Explore how EGFR and KRAS G12C biomarkers reshape lung cancer care, from first-line choices to resistance, testing, and prognosis.
Misty D. Shields, MD, PhD
Advertisement
Articles by Misty D. Shields, MD, PhD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on AJMC
1
Pipeline Advances in Sjögren Disease Bring Targeted Therapies Closer
2
FDA Approves Pirtobrutinib for Untreated CLL/SLL Without 17p Deletion
3
Preparing Practices for the Next Era of Hepatitis B Care
4
Oral Targeted Anticancer Medication Use Following High-Deductible Health Plan Enrollment
5